Jeong Woo Cho, Ph.D., was appointed president and CEO of SK biopharmaceuticals and SK life science in 2017. Dr. Cho began his career at SK in 2001, becoming chief operating officer and executive vice president, leading the enterprise’s drug development business. In that role, he was responsible for managing all activities associated with the clinical development programs for key CNS assets and managed global project teams in the U.S., EU, and Asia. Dr. Cho earned his Ph.D. in biology from the Texas A&M University Graduate School, College Station, Texas USA. He joined the Arvelle Board in 2019.